I n this issue of Diabetes Care, Ko et al. (1) report that in a large group of Hong Kong men and women at increased risk for development of diabetes, borderline elevated fasting plasma glucose (FPG) paired with either borderline elevated GHb or borderline elevated fructosamine (FA) was a strong predictor of diabetes; the "gold standard" for diagnosis of diabetes was the oral glucose tolerance test (OGTT) and World Health Organization (WHO) criteria (1, 2) . That the study population was at increased risk for diabetes was clear from the results; only 55.4% of subjects had normal glucose tolerance using WHO criteria. The investigators recommend that diabetes screening be conducted using FPG paired with either GHb or FA and that OGTT be reserved for only those subjects whose FPG values are not diagnostic for diabetes (using either WHO or American Diabetes Association [ADA] criteria, depending on one's preference), but whose FPG and either GHb or FA values are above an established cutoff (in the study by Ko et al., the cutoffs were close to the upper limits of normal for each of the tests). Thus, at least in the high-risk Hong Kong population studied, ~80% of screening OGTTs could be eliminated.
For anyone who has followed the voluminous scientific literature on diabetes screening and diagnosis over the past 20 years or so, the findings of Ko et al. should come as no great surprise. In fact, more than a decade ago, Little et al. reported that GHb >2 SD above the mean normal value showed very high specificity (91%) and sensitivity (85%) to diagnose diabetes compared with OGTT using WHO criteria (3) . At the time, one criticism of the research findings was that, as in the study by Ko et al., the study population consisted of individuals at high risk for diabetes (Pima Indians); it was thought that study of a more typical patient population with a lower risk for diabetes might show different results. That issue will be settled when the Third National Health and Nutrition Examination Survey, 1988-1994 (NHANES III) results comparing GHb with FPG for diagnosis are reported; the NHANES III data on prevalence of diabetes comparing the new ADA criteria and WHO criteria were recently reported (4). It is noteworthy that a recent meta-analysis of data from 18 studies using GHb versus OGTT for diagnosis concluded that GHb was useful for diagnosis of diabetes (5) .
So, what should those of us who spend much of our time diagnosing and treating diabetes do? Should we follow the advice of Ko et al. and first perform paired FPG and GHb or FA tests on our patients and then perform OGTTs on those whose test values are above whatever cutoff is established? I do not think so. This approach seems like a logistical nightmare, would be excessively expensive, and is unnecessary. First, we should carefully study the new ADA guidelines for diagnosis of diabetes (6) . The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus has proposed that we de-emphasize the OGTT for diagnosis of diabetes and rely on only FPG >126 mg/dl or 7 mmol/1, but at a slightly lower value than used in the WHO criteria. I believe the Expert Committees arguments in favor of this major change are compelling. Thus, it is not necessary to perform both FPG and GHb or FA and then perform OGTT, even in a modest number of patients.
So where does this leave GHb and FA? I believe GHb, and perhaps, FA (the data on FA are difficult to make much sense of, and further studies are needed) should be strongly considered as an alternative to FPG for diabetes screening and should definitely be used as a confirmatory test for diagnosis; the ADA already recommends GHb testing as part of the baseline evaluation in all newly diagnosed patients (7). One frequent criticism of using GHb for diabetes screening and/or diagnosis is that the test is not standardized among laboratories. Thus, each assay method gives different test results, making it virtually impossible to establish specific diagnostic criteria. However, standardization of GHb testing has been accomplished in the U.S. In 1996, the National Glycohemoglobin Standardization Program (NGSP) was established (8) . The purpose of the program is to certify that all GHb assay methods give results comparable to those in the Diabetes Control and Complications Trial (DCCT), the study in which the relationship between glycemic control and microvascular and neuropathic complications was established (9) . To participate in this voluntary program, manufacturers of GHb assay methods first standardize their assay methods to DCCT numbers and then must satisfactorily complete rigorous precision and bias testing to receive a certificate of traceability to the DCCT reference method. The certificate must be renewed annually. Routine clinical laboratories can participate in the program by using a DCCT-certified assay method and enrolling in a proficiency testing program offered by the College of American Pathologists (CAP). CAP sends laboratories fresh blood specimens with target values set by the NGSP network laboratories (individual laboratories can also be certified, a process currently recommended for large-volume reference laboratories). The ADA has recommended that laboratories measuring GHb use only NGSP-certified assay methods and participate in the CAP proficiency testing survey (10) . At present, most of the major assay methods in the U.S. are NGSP certified. This has been a big step in the right direction for improving diabetes care.
So, with standardization of GHb testing a reality, do I think GHb should replace FPG for diabetes screening and/or diagnosis? I believe GHb is a very reasonable alternative to FPG for diabetes screening if the cost per test is close to that of FPG (remember FPG as recommended by the Expert Committee is a laboratory plasma glucose determination, not a reflectance meter blood glucose determination). There are some practical advantages of using GHb rather than FPG for screening. For one, patients need not fast; the test can be performed at any time of day without special preparation. What about using GHb for diagnosis? As much as I like GHb, I believe it should be used to DIABETES CARE, VOLUME 21, NUMBER 8, AUGUST 1998 Editorial confirm the diagnosis established by an elevated FPG (a number of studies have shown that if the FPG is elevated, the GHb is almost always elevated as well).
Finally, and probably most important, the new ADA diabetes diagnostic criteria represent a radical departure from earlier recommendations. They are radical not so much for the change in numbers (from 140 mg/dl or 7.8 mmol/1 to 126 mg/dl or 7.0 mmol/1) or for the move away from the OGTT, but for the recommendation that testing for diabetes be performed in all presumably healthy individuals aged 2:45 years and, if normal, repeated at 3-year intervals. This means lots and lots of testing. I do not think it matters so much if testing is performed with FPG or with GHb (we will wait for the data on FA) but rather that testing be performed.
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